ASSURE

Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation

Coordinatore	STICHTING KATHOLIEKE UNIVERSITEIT    more  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Prof. Nome: Nico Cognome: Karssemeijer Email: send email Telefono: +31 24 3614548
Nazionalità Coordinatore	Netherlands [NL]
Sito del progetto	http://www.assure-project.eu
Totale costo	7˙235˙026 €
EC contributo	5˙608˙543 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-12-01   -   2015-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Prof. Nome: Nico Cognome: Karssemeijer Email: send email Telefono: +31 24 3614548	NL (NIJMEGEN)	coordinator	1˙048˙127.20
2	MEVIS MEDICAL SOLUTIONS AG  Organization address address: UNIVERSITAETSALLEE 29 city: BREMEN postcode: 28359 contact info Titolo: Mr. Nome: Thomas Cognome: Pross Email: send email Telefono: +49 421 22 49 578 30 Fax: +49 421 22 49 512	DE (BREMEN)	participant	796˙125.60
3	BIOMEDIQ AS  Organization address address: FRUEBJERGVEJ 3 city: KOBENHAVN postcode: 2100 contact info Titolo: Ms. Nome: Camilla Cognome: Jørgensen Email: send email Telefono: +45 30589643	DK (KOBENHAVN)	participant	700˙086.80
4	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Dr. Nome: Katherine Cognome: Boylan Email: send email Telefono: +44 161 275 8796 Fax: +44 161 233 0397	UK (MANCHESTER)	participant	687˙413.60
5	MATAKINA UK LIMITED  Organization address address: WALNUT TREE CLOSE 1 city: ELY postcode: CB6 2SQ contact info Titolo: Dr. Nome: Ralph Cognome: Highnam Email: send email Telefono: +44 1353 468 029 Fax: +44 1353 468 028	UK (ELY)	participant	631˙680.75
6	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V  Organization address address: Hansastrasse 27C city: MUENCHEN postcode: 80686 contact info Titolo: Mr. Nome: Christoph Cognome: Schulte Email: send email Telefono: +49 89 1205 2728 Fax: +49 89 1205 7534	DE (MUENCHEN)	participant	566˙798.75
7	Medical Imaging Research Institute  Organization address address: Vangerowstr. 18 city: Heidelberg postcode: 69115 contact info Titolo: Dr. Nome: Johannes Cognome: Gregori Email: send email Telefono: +49 6221 43338813	DE (Heidelberg)	participant	404˙360.00
8	UNIVERSITAT DE GIRONA  Organization address address: PLACA SANT DOMENEC 9 EDIFICI LES ALIGUES city: GIRONA postcode: 17071 contact info Titolo: Dr. Nome: Montserrat Cognome: Estopà Email: send email Telefono: +34 972 41 8869	ES (GIRONA)	participant	355˙290.40
9	UNIVERSITAIR MEDISCH CENTRUM UTRECHT  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Dr. Nome: Carla H Cognome: Van Gils Email: send email Telefono: +31 88 7553014	NL (UTRECHT)	participant	263˙095.20
10	Institut Jules Bordet  Organization address city: Brussels postcode: 1000 contact info Titolo: Ms. Nome: Marielle Cognome: Sautois Email: send email Telefono: 3225413214	BE (Brussels)	participant	155˙565.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'While early detection of breast cancer by screening appears effective, many women derive little or no benefit from screening, due to the way it is currently organized: as a one-size-fits all approach irrespective of personalised risk factors. It is known, however, that some women are at a much higher risk of getting the disease than others, and that mammography is unsuitable for cancer detection in women with dense breasts. The aim of this project is to develop personalised methods to tailor breast cancer screening to the individual needs of the woman. We will propose methods to stratify women at the highest risk to MRI; those with intermediate risk and/or dense breasts to follow-on ultrasound. A risk model will be developed that includes both breast cancer risk and the risk of missing cancers in mammograms. In this model, breast density plays a key role, as one of the largest known risk factors and the factor making mammograms ineffective. Two SMEs focusing on breast density are involved, where academic partners bring unique databases with over 80,000 screening mammograms and associated risk profiles. These are essential for model development, and subsequently for the development of products that benefit all women. Personalised screening is only economically feasible if it is based upon cost-effective strategies. While current methods in breast MRI imaging and breast ultrasound are promising, more efficient protocols must be developed to use these modalities routinely in screening. With leading SMEs and clinical partners, screening procedures will be optimized by developing automated image analysis tools to guide workflow and quality assurance. More efficient MRI protocols will be investigated to reduce time and cost, while the use of novel MRI imaging sequences without intravenous contrast will be explored. Cost-effectiveness of the stratification models will be assessed by combining the risk model with cost and effectiveness of alternative screening strategies.'